James P. Boylan - 10 Jun 2025 Form 4 Insider Report for Immunome Inc. (IMNM)

Role
Director
Signature
/s/ Sandra Stoneman, Attorney-in-Fact
Issuer symbol
IMNM
Transactions as of
10 Jun 2025
Net transactions value
$0
Form type
4
Filing time
12 Jun 2025, 17:00:00 UTC
Previous filing
13 Feb 2025
Next filing
27 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Boylan James P Director C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL /s/ Sandra Stoneman, Attorney-in-Fact 12 Jun 2025 0001953094

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMNM Director Stock Option (right to buy) Award $0 +18,864 $0.000000 18,864 10 Jun 2025 Common Stock 18,864 $9.57 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
F2 The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to Mr. Boylan's continuous service with the Company on each respective vesting date.